Ostatní
Návod 
Theravance Biopharma, Inc.
TBPH
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
0.7B
Obrat
0B
Zisk
0B
Aktiva
0B
Dluh
0B
ROE
13%
ROA
7%
PE
7
PS
7
Cena 1R
8-21
⌀ Cena
13.38
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
25-02-2026
Poslední dividenda
Profil
Theravance Biopharma, Inc., biofarmaceutická společnost, objevuje, vyvíjí a komercializuje respirační léky ve Spojených státech, Evropě a Asii. Společnost nabízí přípravek YUPELRI, nebulizovaný dlouhodobě působící muskarinový antagonista užívaný jednou denně k léčbě chronické obstrukční plicní nemoci (CHOPN). Jeho produktové portfolio zahrnuje také Izencitinib, inhibitor gut-selektivní panjanuskinázy (JAK), který je v klinických studiích fáze IIb/III k léčbě revmatoidní artritidy, myelofibrózy a ulcerózní kolitidy, stejně jako k léčbě řady zánětlivých střevních onemocnění, včetně ulcerózní kolitidy a Crohnovy choroby. Kromě toho portfolio produktů společnosti zahrnuje Ampreloxetin, hodnocený inhibitor zpětného vychytávání noradrenalinu, který dokončil studii fáze III na neurogenní ortostatickou hypotenzi; Nezulcitinib, plicně selektivní, nebulizovaný inhibitor JAK, který je ve fázi II klinického vývoje pro potenciální léčbu hospitalizovaných pacientů s akutním poraněním plic způsobeným COVID-19; inhalační ALK5i, potenciální inhalační antifibrózu, která je ve fázi I pro léčbu idiopatické plicní fibrózy; a TD- 5202, hodnocený, perorálně podávaný, střevní selektivní, ireverzibilní inhibitor JAK3, který je v klinické studii fáze I pro léčbu zánětlivých střevních onemocnění. Dále nabízí TRELEGY pro léčbu CHOPN a astmatu; Velusetrag, perorální a hodnocený lék pro poruchy gastrointestinální motility; a selektivní agonista 5- HT4 pro léčbu poruch gastrointestinální motility. Společnost uzavřela licenční smlouvy a smlouvy o spolupráci se společnostmi Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A a Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. byla založena v roce 2013 a sídlí v George Townu na Kajmanských ostrovech.
Sektor
Healthcare
Odvětví
Biotechnology
Počet zaměstnanců
97
Založení
2014-05-16
Podobné společnosti
$ 13.10
+ $ 0.79
$ 10.02
+ $ 0.29
$ 1.11
+ $ 0.04
$ 8.66
+ $ 0.35
$ 5.36
+ $ 0.23
$ 8.71
- $ 0.02
$ 14.36
+ $ 0.04
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 107.5 | 107.5 | 64.4 | 57.4 | 51.3 | 55.3 | 71.9 | 73.4 | 60.4 | 15.4 | 48.6 | 42.1 | 11.7 | 0.2 | 130.1 | |
| Cost of Revenues | 5.5 | 5.5 | 0.0 | 40.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 6.0 | 2.9 | 4.7 | 4.1 | 0.0 | 0.0 | |
| Gross Profit | 101.9 | 101.9 | 64.4 | 16.8 | 51.3 | 55.3 | 71.9 | 73.4 | 59.7 | 9.4 | 45.8 | 37.5 | 7.6 | 0.2 | 130.1 |
| Revenue | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 45.9 | 20.0 | 26.2 | 15.4 | 18.8 | 16.9 | 14.3 | 14.5 | 17.6 | 15.7 | |
| Cost of Revenues | -24.5 | 8.1 | 10.5 | 11.5 | 0.0 | 9.3 | 10.0 | 9.0 | 4.3 | 1.3 | |
| Gross Profit | 70.4 | 11.9 | 15.7 | 3.9 | 18.8 | 7.6 | 4.3 | 5.5 | 13.2 | 14.4 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 40.6 | 63.4 | 193.7 | 261.0 | 219.2 | 201.3 | 173.9 | 141.7 | 129.2 | 168.5 | 120.6 | 114.0 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 70.1 | 67.1 | 99.3 | 108.7 | 106.1 | 97.1 | 95.6 | 84.5 | 90.2 | 71.6 | 35.9 | 25.7 | |
| Depreciation & Amortization | 2.7 | 5.5 | 3.6 | 6.1 | 21.4 | 125.2 | 71.3 | 42.1 | 3.2 | 4.0 | 3.1 | 3.0 | 2.7 | 2.7 | 3.3 | |
| Total Operating Expenses | 115.2 | 115.2 | 111.3 | 113.5 | 130.5 | 293.0 | 369.6 | 325.3 | 298.4 | 269.5 | 226.2 | 219.4 | 240.2 | 156.5 | 139.7 | |
| Operating Income | -13.2 | -13.2 | -46.9 | -56.0 | -92.0 | -257.8 | -297.8 | -251.9 | -238.8 | -260.1 | -180.5 | -181.9 | -232.5 | -156.3 | -9.6 |
| Operating Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 8.3 | 8.3 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 15.5 | 16.1 | ||
| Depreciation & Amortization | 1.5 | 0.4 | 0.4 | 0.4 | 0.7 | 0.4 | 0.4 | 0.4 | 1.7 | 1.3 | ||
| Total Operating Expenses | 60.1 | 18.3 | 18.4 | 18.4 | 28.0 | 18.4 | 20.0 | 16.7 | 23.8 | 24.5 | ||
| Operating Income | 10.4 | -6.5 | -2.7 | -14.4 | -9.2 | -10.8 | -15.7 | -11.2 | -6.2 | -8.8 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 2.4 | 0.0 | 4.9 | 9.1 | 8.5 | 1.1 | 2.8 | 8.4 | 12.0 | 5.0 | 1.3 | 0.6 | 1.9 | 0.0 | 0.0 | |
| Interest Expense | 2.5 | 2.5 | 2.5 | 2.4 | 6.4 | 46.9 | 44.6 | 31.9 | 10.5 | 8.5 | 1.4 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Expense | 142.5 | 142.5 | 2.3 | 6.8 | -0.9 | 58.2 | 11.2 | 10.2 | 11.2 | -8.0 | -0.1 | 0.6 | 1.9 | 0.0 | 0.0 | |
| IBT | 129.2 | 129.2 | -44.6 | -49.3 | -92.8 | -199.6 | -286.5 | -241.7 | -226.1 | -271.7 | -180.6 | -181.3 | -230.7 | -156.3 | -9.6 | |
| Income Tax Expense | 23.4 | 23.4 | 11.8 | 5.9 | 0.0 | -0.2 | -8.5 | -5.2 | -10.6 | 13.7 | 10.1 | 1.0 | 6.4 | 0.0 | 0.0 | |
| Net Income | 105.9 | 105.9 | -56.4 | -55.2 | -92.8 | -199.4 | -278.0 | -236.5 | -215.5 | -285.4 | -190.7 | -182.2 | -237.0 | -156.3 | -9.6 |
| Net Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 0.0 | 0.0 | 1.5 | 0.9 | 0.9 | 1.4 | 1.1 | 1.4 | 1.8 | 1.8 | ||
| Interest Expense | 0.6 | 0.6 | 0.7 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | ||
| Other Expense | 62.7 | 3.6 | 75.9 | 0.3 | 0.3 | 0.8 | 0.5 | 0.8 | 1.2 | 1.2 | ||
| IBT | 73.1 | -2.9 | 73.2 | -14.1 | -8.9 | -10.1 | -15.2 | -10.4 | -5.0 | -7.6 | ||
| Income Tax Expense | 12.0 | -6.5 | 18.4 | -0.6 | 6.6 | 2.6 | 1.3 | 1.3 | 3.5 | 1.4 | ||
| Net Income | 61.0 | 3.6 | 54.8 | -13.6 | -15.5 | -12.7 | -16.5 | -11.7 | -8.5 | -9.0 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $-1.00 | $-1.26 | $-2.87 | $-4.46 | $-4.25 | $-3.99 | $-5.45 | $-4.26 | $-5.34 | $-7.46 | $-4.84 | $-0.30 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $-1.00 | $-1.26 | $-2.87 | $-4.46 | $-4.25 | $-3.99 | $-5.45 | $-4.26 | $-5.34 | $-7.46 | $-4.84 | $-0.30 | |
| Shares Outstanding | 50.9 | 50.3 | 48.8 | 55.3 | 73.6 | 69.5 | 62.3 | 55.6 | 54.0 | 52.4 | 44.7 | 34.2 | 31.8 | 32.3 | 32.3 | |
| Diluted Shares Outstanding | 53.1 | 51.5 | 48.8 | 55.3 | 73.6 | 69.5 | 62.3 | 55.6 | 54.0 | 52.4 | 44.7 | 34.2 | 31.8 | 32.3 | 32.3 |
| Per Share Data | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.17 | $-0.17 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.17 | $-0.17 | ||
| Shares Outstanding | 50.9 | 50.5 | 50.2 | 49.7 | 49.3 | 49.0 | 48.7 | 48.3 | 49.4 | 52.4 | ||
| Diluted Shares Outstanding | 53.1 | 51.9 | 50.7 | 49.7 | 49.3 | 49.0 | 48.7 | 48.3 | 49.4 | 52.4 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 46.3 | 37.8 | 39.5 | 298.2 | 90.0 | 81.5 | 58.1 | 378.0 | 89.0 | 344.7 | 112.7 | 89.2 | 0.0 | |
| Short Term Investments | 49.7 | 50.6 | 62.9 | 29.3 | 83.5 | 211.5 | 222.8 | 127.3 | 259.6 | 156.4 | 59.7 | 165.4 | 0.0 | |
| Total Cash & ST Investments | 96.1 | 88.4 | 102.4 | 327.5 | 173.5 | 292.9 | 280.8 | 505.3 | 348.6 | 501.1 | 172.4 | 306.0 | 0.0 | |
| Accounts Receivable | 14.3 | 68.4 | 17.5 | 16.8 | 57.6 | 69.7 | 50.6 | 10.1 | 7.1 | 9.1 | 37.2 | 2.1 | 1.1 | |
| Inventory | 0.0 | 0.0 | 0.0 | 1.5 | 10.2 | 20.4 | 0.0 | 0.0 | 16.8 | 12.2 | 10.0 | 12.5 | 10.4 | |
| Other Current Assets | 8.9 | 4.3 | 13.6 | 7.7 | 8.6 | 10.4 | 7.1 | 17.5 | 6.0 | 3.1 | 5.1 | 8.2 | 2.6 | |
| Total Current Assets | 119.3 | 161.1 | 133.5 | 353.5 | 249.9 | 393.3 | 338.5 | 532.8 | 378.7 | 528.5 | 237.5 | 326.8 | 14.1 |
| Current Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 329.7 | 281.9 | 110.6 | 37.8 | 23.4 | 46.3 | 53.8 | 39.5 | 71.7 | -42.5 | |
| Short Term Investments | 0.0 | 56.9 | 20.2 | 50.6 | 68.0 | 49.7 | 46.1 | 62.9 | 62.3 | 210.0 | |
| Total Cash & ST Investments | 329.7 | 338.8 | 130.9 | 88.4 | 91.4 | 96.1 | 100.0 | 102.4 | 134.0 | 167.5 | |
| Accounts Receivable | 18.3 | 21.9 | 15.4 | 68.4 | 16.8 | 14.3 | 14.7 | 17.5 | 17.1 | 15.8 | |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.6 | 1.0 | |
| Other Current Assets | 6.8 | 5.6 | 4.1 | 4.3 | 8.3 | 8.9 | 9.7 | 13.6 | 10.6 | 8.8 | |
| Total Current Assets | 354.7 | 366.3 | 150.3 | 161.1 | 116.5 | 119.3 | 124.3 | 133.5 | 161.7 | 192.0 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 40.0 | 35.8 | 45.4 | 52.0 | 53.3 | 59.7 | 59.2 | 13.2 | 10.2 | 8.5 | 9.9 | 9.7 | 10.2 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Long-Term Investments | 0.8 | 0.0 | 0.0 | 0.0 | 67.5 | 12.8 | 5.0 | 11.9 | 41.6 | 91.6 | 50.9 | 51.4 | 0.0 | |
| Other Long-Term Assets | 201.9 | 157.3 | 203.1 | 201.9 | 4.1 | 3.3 | 6.1 | 2.4 | 10.9 | 10.7 | 1.9 | -50.1 | 0.8 | |
| Total Long-Term Assets | 242.7 | 193.1 | 248.5 | 253.9 | 124.9 | 75.7 | 70.3 | 27.4 | 62.7 | 110.8 | 62.6 | 11.0 | 11.1 | |
| Total Assets | 362.0 | 354.2 | 382.0 | 607.4 | 374.8 | 469.1 | 408.8 | 560.2 | 441.4 | 639.3 | 300.1 | 337.8 | 25.2 |
| Long-Term Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 31.7 | 33.1 | 34.5 | 35.8 | 37.1 | 40.0 | 44.1 | 45.4 | 46.9 | 48.0 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Long-Term Investments | 3.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.8 | 0.8 | 0.8 | |
| Other Long-Term Assets | 26.0 | 26.6 | 158.9 | 157.3 | 202.5 | 202.8 | 202.9 | 202.3 | 204.2 | 205.8 | |
| Total Long-Term Assets | 60.8 | 59.7 | 193.3 | 193.1 | 239.6 | 242.7 | 247.0 | 248.5 | 251.9 | 254.6 | |
| Total Assets | 415.5 | 426.0 | 343.6 | 354.2 | 356.1 | 362.0 | 371.3 | 382.0 | 413.6 | 446.6 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 1.7 | 2.2 | 1.5 | 1.6 | 3.1 | 6.8 | 4.8 | 9.0 | 5.9 | 1.7 | 18.8 | 9.9 | 6.9 | |
| Short-Term Debt | 4.2 | 10.7 | 7.8 | 28.7 | 17.4 | 29.2 | 17.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Current Liabilities | 22.9 | 13.3 | 15.4 | -1.6 | 37.9 | 76.1 | 57.8 | 46.1 | 56.5 | 47.4 | 30.5 | 31.2 | 21.7 | |
| Current Liabilities | 22.9 | 32.1 | 24.8 | 28.7 | 58.6 | 123.6 | 111.7 | 98.6 | 62.6 | 49.3 | 49.5 | 41.3 | 36.9 |
| Current Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 0.0 | 1.7 | 2.4 | 2.2 | 1.5 | 1.7 | 1.7 | 1.5 | 2.4 | 1.6 | |
| Short-Term Debt | 0.0 | 10.9 | 10.8 | 10.7 | 4.2 | 4.2 | 4.1 | 7.8 | 19.4 | 18.3 | |
| Other Current Liabilities | 37.4 | 15.4 | 12.4 | 13.3 | 17.8 | 17.1 | 15.9 | 15.4 | 0.5 | 3.9 | |
| Current Liabilities | 37.4 | 54.6 | 31.5 | 32.1 | 23.4 | 22.9 | 21.7 | 24.8 | 25.4 | 24.5 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 42.4 | 39.1 | 45.2 | 45.4 | 652.1 | 647.1 | 492.9 | 454.4 | 223.7 | 222.7 | 0.0 | 0.0 | 0.0 | |
| Capital Leases | 42.4 | 49.8 | 49.2 | 74.1 | 52.7 | 47.2 | 47.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Def. Tax Liability | 69.0 | 0.0 | 0.0 | 0.0 | -0.3 | -0.3 | -6.8 | -26.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 168.3 | 178.6 | 169.0 | 165.6 | 713.4 | 772.8 | 632.7 | 611.8 | 326.2 | 289.0 | 57.1 | 48.0 | 42.2 |
| Long-Term Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 33.7 | 35.6 | 37.3 | 39.1 | 40.8 | 42.4 | 43.8 | 90.5 | 82.2 | 85.0 | |
| Capital Leases | 33.7 | 46.5 | 48.2 | 49.8 | 45.0 | 46.7 | 47.9 | 45.2 | 41.1 | 42.5 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 70.4 | -0.2 | -0.2 | |
| Total Liabilities | 182.8 | 201.2 | 177.6 | 178.6 | 170.5 | 168.3 | 166.4 | 169.0 | 167.5 | 166.5 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 193.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Retained Earnings | -937.3 | -965.5 | -909.1 | -853.9 | -1,726.0 | -1,526.6 | -1,248.6 | -1,012.1 | -797.7 | -512.2 | -321.6 | -139.3 | -17.0 | |
| Comprehensive Income | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 | 0.1 | -0.2 | -0.7 | -0.3 | -0.1 | -0.1 | 0.0 | |
| Total Common Equity | 193.7 | 175.5 | 213.0 | 441.8 | -338.6 | -303.8 | -223.8 | -51.6 | 115.2 | 350.2 | 243.1 | 289.8 | -17.0 |
| Total Common Equity | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 232.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Retained Earnings | 0.0 | -924.3 | -979.1 | -965.5 | -950.0 | -937.3 | -920.8 | -909.1 | -900.6 | -891.6 | |
| Comprehensive Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | -0.1 | -0.2 | -0.3 | |
| Total Common Equity | 232.7 | 224.8 | 166.0 | 175.5 | 185.7 | 193.7 | 204.9 | 213.0 | 246.1 | 280.2 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 46.7 | 49.8 | 49.2 | 74.1 | 652.1 | 647.1 | 492.9 | 454.4 | 223.7 | 222.7 | 0.0 | 0.0 | 0.0 | |
| Book Value | 193.7 | 175.5 | 213.0 | 441.8 | -338.6 | -303.8 | -223.8 | -51.6 | 115.2 | 350.2 | 243.1 | 289.8 | -17.0 |
| Other | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Book Value | 232.7 | 224.8 | 166.0 | 175.5 | 185.7 | 193.7 | 204.9 | 213.0 | 246.1 | 280.2 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -45.7 | 105.9 | -56.4 | -55.2 | -92.8 | -199.4 | -278.0 | -236.5 | -215.5 | -285.4 | -190.7 | -182.2 | -237.0 | -156.3 | -9.6 | |
| Depreciation & Amortization | 5.4 | 5.6 | 3.6 | 4.3 | 7.0 | 9.7 | 9.1 | 6.2 | 3.2 | 4.0 | 3.1 | 3.0 | 2.7 | 2.7 | 3.3 | |
| Stock-Based Compensation | 22.7 | 18.5 | 21.4 | 25.4 | 39.7 | 62.1 | 63.0 | 60.5 | 51.3 | 49.1 | 41.2 | 54.1 | 43.2 | 22.5 | 21.3 | |
| Change Working Capital | 2.1 | 120.5 | 20.4 | -8.3 | 42.4 | -39.6 | -39.5 | -45.4 | 59.4 | 22.4 | 46.9 | -37.8 | 12.8 | 10.2 | -134.3 | |
| Change In Accounts Receivable | 1.5 | -27.1 | -1.0 | 0.0 | -2.7 | 1.8 | 6.1 | -11.3 | 1.6 | -1.6 | 1.3 | -1.6 | -0.1 | -0.2 | -2.7 | |
| Change In Accounts Payable | 0.1 | 0.3 | 0.8 | 0.0 | -1.6 | -3.5 | 3.7 | -4.3 | 3.6 | 3.8 | -16.4 | 8.7 | 3.9 | 2.1 | -1.5 | |
| Change In Inventories | -3.5 | 0.0 | 0.0 | 0.0 | 0.0 | -26.4 | -22.5 | 1.4 | -1.6 | -7.3 | -3.2 | 1.0 | -6.6 | -3.1 | -4.8 | |
| Other Non-cash Items | 19.3 | -0.4 | 7.1 | 3.7 | -183.3 | 3.9 | -20.4 | -23.0 | 0.0 | 0.0 | 0.2 | -8.1 | 3.2 | 0.0 | 0.2 | |
| Cash from Operations | -8.8 | 0.0 | 0.0 | -27.0 | -187.0 | -207.9 | -250.4 | -238.2 | -112.9 | -201.1 | -99.0 | -168.9 | -175.2 | -121.0 | -119.1 |
| Cash Flow From Operating Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 61.0 | 3.6 | 54.8 | -13.6 | -15.5 | -12.7 | -16.5 | -11.7 | -8.5 | -9.0 | |
| Depreciation & Amortization | 0.4 | 0.6 | 0.9 | 1.1 | 0.7 | 0.8 | 1.0 | 1.2 | 1.4 | 0.9 | |
| Stock-Based Compensation | 4.5 | 4.6 | 4.5 | 4.9 | 5.8 | 5.0 | 5.4 | 5.2 | 5.8 | 6.3 | |
| Change Working Capital | 261.7 | -16.9 | 157.8 | 51.9 | 13.9 | -0.3 | 2.7 | 4.1 | -3.4 | -1.3 | |
| Change In Accounts Receivable | 99.6 | 3.7 | -6.6 | 53.1 | -1.6 | -2.5 | 0.4 | 2.8 | -0.4 | -1.3 | |
| Change In Accounts Payable | 0.4 | 0.5 | -0.7 | 0.2 | 0.8 | -0.2 | 0.0 | 0.2 | -0.3 | 0.3 | |
| Change In Inventories | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -4.8 | 1.3 | |
| Other Non-cash Items | -333.7 | 0.6 | 0.7 | 0.6 | 0.8 | 2.0 | 3.6 | 0.6 | 1.9 | 0.6 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.9 | -2.5 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -0.8 | 0.0 | -0.3 | -2.5 | -0.6 | -3.4 | -6.6 | -3.2 | -7.2 | -2.4 | -2.1 | -2.6 | -3.1 | -2.7 | -2.6 | |
| Acquisitions | -1.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.0 | 20.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Investments | -58.1 | -248.2 | -143.0 | -134.5 | -103.1 | -158.3 | -402.0 | -423.9 | -183.3 | -288.8 | -237.6 | -73.0 | -168.9 | 0.0 | 0.0 | |
| Sales of Investment | 72.3 | 143.0 | 155.7 | 102.8 | 158.0 | 286.2 | 419.3 | 339.0 | 347.2 | 234.9 | 91.5 | 186.7 | 66.4 | 0.0 | 0.0 | |
| Other Investing Activities | 18.6 | 0.0 | 0.0 | 1.5 | 1,099.7 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.7 | 0.1 | 0.2 | |
| Cash from Investing | 13.3 | 0.0 | 0.0 | -32.7 | 1,154.0 | 124.5 | 10.7 | -83.1 | 176.7 | -56.3 | -148.2 | 111.0 | -106.3 | -2.6 | -2.4 |
| Cash Flow From Investing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | 0.0 | 0.0 | 0.0 | 0.0 | -0.2 | 0.0 | 0.0 | -0.1 | -0.7 | 0.0 | |
| Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.5 | 0.0 | |
| Investments | -64.9 | -124.7 | -56.6 | -2.0 | -40.0 | -44.9 | -31.2 | -26.9 | 0.0 | 0.0 | |
| Sales of Investment | 65.5 | 24.5 | 20.4 | 32.6 | 55.9 | 27.5 | 28.2 | 44.0 | 0.0 | 0.0 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.5 | 0.0 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.7 | 0.0 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | -631.6 | -10.7 | -246.8 | -2.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | |
| Debt Issued | 4.1 | 49.8 | 0.7 | -25.0 | 53.7 | 15.7 | 401.0 | 40.7 | 230.6 | 1.1 | 222.7 | 0.0 | 0.0 | 0.0 | 0.1 | |
| Issuance of Common Stock | 0.7 | 0.0 | 0.0 | 0.0 | 0.0 | 108.2 | 139.9 | 3.5 | 0.0 | 0.0 | 253.0 | 79.0 | 0.0 | 0.0 | 0.0 | |
| Repurchase of Common Stock | -64.4 | -4.0 | -3.1 | -199.6 | -132.3 | -9.1 | -9.7 | -3.2 | -9.8 | -8.6 | -3.9 | -0.8 | -0.2 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -385.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | -1.8 | 0.0 | 0.0 | 0.6 | 5.1 | 3.5 | 764.8 | 3.1 | 235.0 | 10.2 | 230.1 | 3.0 | 370.8 | 123.6 | 121.6 | |
| Cash from Financing | -63.8 | 0.0 | 0.0 | -198.9 | -758.8 | 91.9 | 263.1 | 1.3 | 225.2 | 1.7 | 479.2 | 81.3 | 370.6 | 123.6 | 121.5 |
| Cash Flow From Financing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Debt Issued | 33.7 | -12.8 | -1.7 | -1.7 | 4.8 | -1.7 | -1.2 | 2.7 | 4.1 | -1.4 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Repurchase of Common Stock | -2.0 | -0.7 | -0.5 | -0.9 | -0.5 | -0.4 | -0.5 | -1.7 | -30.8 | -31.4 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -30.6 | -31.4 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -59.3 | 130.0 | -1.7 | -258.6 | 208.2 | 8.5 | 23.4 | -320.0 | 289.0 | -255.7 | 232.0 | 23.5 | 370.6 | 0.0 | 0.0 | |
| Closing Cash Balance | 46.3 | 168.6 | 38.6 | 40.4 | 299.0 | 90.8 | 82.3 | 58.9 | 378.9 | 89.0 | 344.7 | 112.7 | 89.2 | 0.0 | 0.0 |
| Cash position | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -7.0 | -107.2 | 171.3 | 72.8 | 14.4 | -23.0 | -7.5 | 14.3 | -32.1 | -33.9 | |
| Closing Cash Balance | 168.6 | 174.8 | 282.8 | 111.5 | 38.6 | 24.2 | 47.2 | 54.7 | 40.4 | 72.5 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -9.6 | 238.5 | -11.9 | -29.5 | -187.6 | -211.3 | -257.0 | -241.4 | -120.1 | -203.5 | -101.1 | -171.5 | -178.3 | -123.7 | -121.7 | |
| Real Free Cash Flow | -32.3 | 220.0 | -33.3 | -54.9 | -227.3 | -273.3 | -320.0 | -301.8 | -171.4 | -252.6 | -142.3 | -225.6 | -221.5 | -146.2 | -143.0 |
| Free Cash Flow | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -6.1 | -6.5 | 208.0 | 43.0 | -1.1 | -5.2 | -4.5 | -1.1 | -1.5 | -2.5 | |
| Real Free Cash Flow | -10.6 | -11.1 | 203.5 | 38.2 | -6.9 | -10.2 | -9.8 | -6.3 | -7.4 | -8.8 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | 7.2 | -2.6 | -1.4 |
| P/S | 7.1 | 34.3 | 9.4 |
| P/B | 3.3 | -1.5 | 5.2 |
| P/FCF | 3.5 | -4.1 | -1.5 |
| Market cap | $0.7 | $0.7 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 8.1 % | 50.8 % | 0 % |
| Debt to Income | 31.8 % | -101.2 % | 0 % |
| Debt to Free cash flow | 15.3 % | -50.4 % | 0 % |
| Interest expense percentage | -18.6 % | -8 % | 44.7 % |
| Current ratio | 9.5 | 5.6 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | 45.5 % | 94 % | 0 % |
| ROA | 25.5 % | -60.8 % | 0 % |
| CapEx to Revenue | 0.3 % | 277.3 % | 0 % |
| RaD to Revenue | 0 % | 11608.5 % | 0 % |
| ROEM | 1,107,876.3 | 195261.6 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 62.6 % | 91.8 % | 68.7 % |
| Operating margin | -40.9 % | -14831 % | 35.5 % |
| Net margin | 36.5 % | -14681 % | 9.5 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 7.3 % | 0 % |
| Dividend payout percentage | 0 % | -26.8 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 51.9 mil | 51.3 mil |
| Employee count | 0.1 tis | 0.3 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
